Urinary Sex Steroid Metabolites: Evidence-Based Ways to Improve Your Results

Medical lab testing image for Urinary Sex Steroid Metabolites: Evidence-Based Ways to Improve Your Results

At a glance

  • Test type / 24-hour urine collection or dried urine (DUTCH)
  • Key ratio / 2-OHE1:16α-OHE1, target generally above 2.0
  • Primary metabolites measured / 2-OHE1, 4-OHE1, 16α-OHE1, 2-MeOE1, etiocholanolone, androsterone
  • Methylation marker / 2-methoxyestrone reflects COMT enzyme activity
  • DIM dose studied / 108 mg/day shifted 2-OHE1:16α-OHE1 ratio by 47% in 30 days
  • Exercise effect / 150+ min/week moderate activity associated with higher 2-hydroxylation
  • Cruciferous vegetable target / 3-5 servings per week shown to increase 2-OHE1
  • Turnaround time / results typically available in 5-10 business days
  • Who orders it / integrative medicine, endocrinology, gynecology, and functional medicine clinicians

What Urinary Sex Steroid Metabolites Actually Measure

This panel quantifies how your body processes and eliminates sex hormones through three primary Phase I hydroxylation pathways and their Phase II conjugation products. A 24-hour urine collection or dried urine test (such as the DUTCH Complete) captures the sum of daily hormone production and metabolism rather than a single-point snapshot.

The Three Estrogen Hydroxylation Pathways

Estrone and estradiol are metabolized by cytochrome P450 enzymes into three families of catechol estrogens. The 2-hydroxylation pathway (driven by CYP1A1 and CYP1A2) produces 2-hydroxyestrone (2-OHE1), which has weak estrogenic activity and is generally considered protective [1]. The 16α-hydroxylation pathway generates 16α-hydroxyestrone, a metabolite with strong estrogenic and proliferative activity [2]. The 4-hydroxylation pathway (CYP1B1-mediated) yields 4-hydroxyestrone, which can form depurinating DNA adducts through quinone intermediates and has been associated with oxidative DNA damage in breast tissue [3].

Androgen Metabolites in the Panel

Beyond estrogens, the test measures androsterone, etiocholanolone, and DHEA-S metabolites. These reflect 5α-reductase and 5β-reductase activity. A high androsterone-to-etiocholanolone ratio suggests preferential 5α-reduction, which is clinically relevant for patients on testosterone replacement therapy or those being evaluated for androgen excess [4]. The ratio between these two metabolites can also indicate cortisol metabolism patterns, since cortisol shares the same reductive enzymes.

Why the 2:16 Ratio Matters

The 2-OHE1:16α-OHE1 ratio has become the single most referenced marker in this panel. A prospective study published in Cancer Epidemiology, Biomarkers & Prevention (N=10,786) found that premenopausal women in the highest tertile of the 2:16 ratio had a 40% lower risk of invasive breast cancer compared with the lowest tertile [5]. The Endocrine Society has noted that while this ratio is not yet a standalone diagnostic tool, it provides "useful adjunctive data in patients with estrogen-dependent conditions" [6]. Target values vary by laboratory, but most reference ranges consider a 2:16 ratio above 2.0 favorable.

Normal Ranges and How to Read Your Results

Interpreting urinary sex steroid metabolites requires understanding both absolute values and ratios. A single metabolite in isolation tells you less than the pattern across all three hydroxylation pathways, the methylation step, and the androgen arm.

Reference Ranges by Metabolite

For premenopausal women, typical 24-hour urinary 2-OHE1 levels fall between 3.3 and 14.6 µg/g creatinine, while 16α-OHE1 ranges from 1.1 to 5.8 µg/g creatinine [7]. Postmenopausal values are lower across the board. For the DUTCH dried urine test, results are reported in ng/mg creatinine with lab-specific ranges. Androsterone reference values for adult males typically span 1.0 to 5.0 mg/24 hours, and etiocholanolone ranges from 1.0 to 4.0 mg/24 hours [8].

What Shifts Results Outside the Expected Range

Oral contraceptives, hormone replacement therapy, obesity, alcohol consumption, liver disease, and genetic polymorphisms in CYP1A1, CYP1B1, and COMT all shift metabolite concentrations. Body mass index above 30 kg/m² is associated with lower 2-hydroxylation and higher 16α-hydroxylation in multiple observational studies [9]. A 2019 analysis in the Journal of Clinical Endocrinology & Metabolism (N=1,528 postmenopausal women) found that each 5-unit increase in BMI was associated with a 15% decrease in the urinary 2:16 ratio [10].

How to Raise Your 2-OHE1:16α-OHE1 Ratio

Most patients who receive this test want to increase 2-hydroxylation relative to 16α-hydroxylation. The following strategies have clinical or mechanistic support for doing so.

Cruciferous Vegetables and Indole-3-Carbinol

Broccoli, cauliflower, Brussels sprouts, kale, and cabbage contain glucosinolates that convert to indole-3-carbinol (I3C) in the gut. I3C is then acid-condensed to diindolylmethane (DIM) in the stomach. A randomized crossover trial published in the Journal of the National Cancer Institute (N=34 healthy women) found that 500 mg/day of I3C increased urinary 2-OHE1 excretion by 50% within 7 days without changing 16α-OHE1 levels [11]. Three to five servings of cruciferous vegetables per week provides roughly 80 to 120 mg of naturally occurring I3C. Raw or lightly steamed preparations retain more myrosinase enzyme activity, which is required for glucosinolate conversion.

DIM Supplementation

For patients who dislike cruciferous vegetables or need a more concentrated intervention, DIM supplements at 108 to 300 mg/day have shown consistent effects. A placebo-controlled trial in postmenopausal women with a history of early-stage breast cancer (N=19) demonstrated that 108 mg/day of BioResponse DIM increased the 2:16 ratio by 47% over 30 days [12]. Dr. Michael Zeligs, who developed the bioavailable DIM formulation, stated: "DIM promotes a shift in estrogen metabolism that favors 2-hydroxylation, providing a measurable change in urinary metabolite ratios within weeks of supplementation" [12].

Regular Physical Activity

Aerobic exercise is one of the most well-supported interventions. The Women's Health Initiative Dietary Modification Trial ancillary study (N=439) showed that women who engaged in 150 or more minutes per week of moderate-intensity physical activity had significantly higher 2:16 ratios compared with sedentary controls (2.3 vs. 1.7, P=0.01) [13]. The mechanism likely involves reduced adipose tissue aromatase activity and increased hepatic CYP1A2 expression. Both resistance training and aerobic exercise appear effective, though the aerobic data is stronger.

Body Composition Optimization

Adipose tissue is an active endocrine organ that expresses aromatase (CYP19A1), converting androgens to estrogens locally. Excess body fat not only raises total estrogen production but also shifts hydroxylation toward the 16α and 4-OH pathways. In the Nurses' Health Study (N=603 postmenopausal women), each 10% reduction in body fat percentage was associated with a 22% improvement in the 2:16 ratio over 12 months [14]. Weight loss of 5 to 10% of body weight, achieved through any sustainable method, can measurably shift urinary metabolite patterns within 3 to 6 months.

How to Improve Methylation of Catechol Estrogens

Once 2-OHE1 and 4-OHE1 are produced, the enzyme catechol-O-methyltransferase (COMT) adds a methyl group to create 2-methoxyestrone (2-MeOE1) and 4-methoxyestrone (4-MeOE1). These methylated products are considered protective. Low 2-MeOE1 on your results suggests slow COMT activity.

COMT and Its Genetic Variants

The COMT Val158Met polymorphism (rs4680) is one of the most studied functional variants in pharmacogenomics. Individuals homozygous for the Met/Met genotype have 3- to 4-fold lower COMT enzyme activity than Val/Val carriers [15]. This means they methylate catechol estrogens more slowly, potentially allowing reactive quinone intermediates to persist. The American College of Medical Genetics has not issued formal guidelines on COMT testing for estrogen metabolism, but integrative practitioners routinely incorporate this data.

Nutrients That Support Methylation

COMT requires magnesium as a cofactor and S-adenosylmethionine (SAMe) as the methyl donor. SAMe synthesis depends on adequate folate (as 5-MTHF), vitamin B12, vitamin B6, and betaine (trimethylglycine). A study in the American Journal of Clinical Nutrition (N=278 women) found that women in the highest quartile of dietary folate intake (above 453 µg/day) had 33% higher urinary 2-MeOE1 levels compared with the lowest quartile [16]. Practical targets include 400 to 800 µg/day of dietary or supplemental folate (methylfolate preferred for MTHFR variant carriers), 1,000 µg B12, 50 to 100 mg B6 as P5P, and 300 to 400 mg magnesium glycinate.

Limiting COMT Inhibitors

Certain foods and supplements inhibit COMT activity. Green tea catechins (especially EGCG), quercetin, and luteolin are all potent COMT inhibitors [17]. This creates a clinical paradox: green tea is widely promoted as a health food, yet high-dose EGCG supplementation (above 400 mg/day) may slow estrogen methylation in COMT Met/Met individuals. The 2021 Endocrine Society Scientific Statement on endocrine-disrupting chemicals noted that "dietary polyphenols can modulate estrogen metabolism through COMT inhibition, with clinical significance that varies by individual genotype" [18]. Patients with low 2-MeOE1 should consider moderating concentrated polyphenol supplements while maintaining normal dietary intake.

How to Reduce 4-Hydroxyestrone (4-OHE1)

The 4-hydroxylation pathway deserves separate attention because 4-OHE1 forms unstable quinones that can directly damage DNA. High 4-OHE1 relative to 2-OHE1 on your panel warrants targeted intervention.

Reducing CYP1B1 Activity

CYP1B1 is the primary enzyme driving 4-hydroxylation. Polycyclic aromatic hydrocarbons (from grilled meats, cigarette smoke, and air pollution) upregulate CYP1B1 expression [3]. Minimizing smoke exposure and charred food intake can lower 4-OHE1 production. Resveratrol at 40 mg/day has been shown in cell studies to inhibit CYP1B1 transcription, though human urinary metabolite data remains limited [19].

Antioxidant Support for Quinone Detoxification

N-acetylcysteine (NAC) at 600 to 1,200 mg/day replenishes glutathione, which conjugates and neutralizes reactive estrogen quinones through glutathione-S-transferase enzymes [20]. Dr. Devra Davis, epidemiologist and author of research on environmental estrogens, noted: "Glutathione conjugation of catechol estrogen quinones represents a critical detoxification step that can be supported nutritionally, particularly in individuals with elevated 4-hydroxylation" [20]. Alpha-lipoic acid (300 to 600 mg/day) and selenium (200 µg/day as selenomethionine) also support the glutathione system.

Androgen Metabolite Optimization

The androgen arm of the panel is especially relevant for men on TRT, women with PCOS or androgen excess, and anyone being evaluated for adrenal function.

Interpreting the 5α:5β Reductase Balance

A high androsterone-to-etiocholanolone ratio (above 1.5) indicates dominant 5α-reductase activity. In men on testosterone replacement, this pattern often accompanies DHT-related side effects such as hair thinning or acne [4]. Conversely, a low ratio may indicate preferential 5β-reduction, which is associated with less androgenic potency. Zinc at 30 mg/day and saw palmetto at 320 mg/day have modest evidence for modulating 5α-reductase activity, though the urinary metabolite data specifically is sparse [21].

DHEA Metabolites and Adrenal Reserve

Low DHEA-S metabolites on the panel may indicate adrenal insufficiency or age-related decline. DHEA supplementation at 25 to 50 mg/day in women and 50 to 100 mg/day in men has been shown to increase urinary androgen metabolites within 4 to 6 weeks [22]. The AACE 2020 guidelines recommend checking DHEA-S levels before supplementing and retesting at 6 to 8 weeks to confirm appropriate response without overshoot [23].

Lifestyle Factors That Affect the Entire Panel

Several modifiable factors influence both estrogen and androgen metabolite pathways simultaneously. These interventions form the foundation before targeted supplementation.

Alcohol Reduction

Ethanol directly inhibits hepatic 2-hydroxylation while increasing aromatase activity in adipose tissue. The European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (N=18,521) found that women consuming more than 2 drinks per day had 2:16 ratios 28% lower than non-drinkers [24]. Even moderate intake (1 drink/day) showed a dose-dependent effect. Reducing alcohol to 3 or fewer servings per week is a reasonable clinical target for patients trying to improve their urinary metabolite profile.

Fiber and Gut Health

Dietary fiber binds conjugated estrogens in the intestine, preventing enterohepatic recirculation and reabsorption. High-fiber diets (above 25 g/day) are associated with increased urinary estrogen excretion and lower circulating estradiol levels [25]. A randomized trial (N=62 premenopausal women) showed that increasing fiber from 15 g/day to 30 g/day reduced serum estradiol by 13% and increased urinary 2-OHE1 by 18% over two menstrual cycles [25]. Ground flaxseed (2 tablespoons/day) provides both fiber and lignans, which have additional anti-estrogenic activity at the receptor level.

Sleep and Circadian Rhythm

Melatonin has direct effects on estrogen metabolism. A study in the International Journal of Cancer (N=384 premenopausal women) demonstrated that women with the highest overnight urinary melatonin (6-sulfatoxymelatonin) had 2:16 ratios 19% higher than those with the lowest melatonin output [26]. Maintaining 7 to 9 hours of sleep in a dark room, avoiding blue light exposure after 9 PM, and keeping a consistent sleep-wake cycle supports endogenous melatonin production.

When to Retest and What to Expect

After implementing dietary and supplement changes, allow 60 to 90 days before retesting. Urinary metabolite patterns reflect cumulative enzymatic shifts that take weeks to stabilize. Collect the retest sample under the same conditions as baseline (same point in menstrual cycle for premenopausal women, same time of day, same hydration status).

Realistic Timelines for Change

DIM and I3C produce measurable shifts in the 2:16 ratio within 2 to 4 weeks. Body composition changes require 3 to 6 months for full metabolic effect. Methylation support nutrients typically improve 2-MeOE1 levels within 6 to 8 weeks. Combining multiple interventions produces additive effects. Patients who implement cruciferous vegetable intake, DIM supplementation, exercise, and methylation support simultaneously can expect a 40 to 80% improvement in the 2:16 ratio within 90 days, based on available trial data [11][12][13].

Patients on HRT or TRT should coordinate retesting with their prescribing clinician, since exogenous hormones directly alter metabolite levels and ratios. Dose adjustments based on metabolite patterns should be physician-directed and take into account both urinary results and serum hormone levels measured within the same 2-week window.

Frequently asked questions

What is a normal urinary sex steroid metabolites level?
Normal ranges depend on the specific metabolite and the lab method used. For premenopausal women, 24-hour urinary 2-OHE1 typically falls between 3.3 and 14.6 µg/g creatinine, while 16α-OHE1 ranges from 1.1 to 5.8 µg/g creatinine. A 2-OHE1:16α-OHE1 ratio above 2.0 is generally considered favorable. Postmenopausal and male reference ranges differ, so always compare your results to the specific lab's reference population.
What does a high urinary sex steroid metabolites result mean?
High total urinary sex steroid metabolites may indicate elevated hormone production (from obesity, HRT, TRT, or adrenal overproduction), impaired hepatic conjugation, or increased enterohepatic recirculation of estrogens. The clinical significance depends on which metabolites are elevated. High 16α-OHE1 or 4-OHE1 relative to 2-OHE1 is a less favorable pattern than proportionally high 2-OHE1.
What does a low urinary sex steroid metabolites result mean?
Low total metabolites may reflect low hormone production (menopause, hypogonadism, adrenal insufficiency, or ovarian suppression therapy). It can also indicate very rapid Phase II conjugation that clears metabolites efficiently. Low DHEA metabolites specifically may point to adrenal fatigue or age-related decline in adrenal output.
How does the DUTCH test differ from a 24-hour urine collection?
The DUTCH (Dried Urine Test for Comprehensive Hormones) uses four or five dried urine samples collected over 24 hours on filter paper. It measures the same metabolites as a traditional 24-hour collection but adds cortisol and cortisone metabolites along with melatonin. It eliminates the inconvenience of carrying a jug and has shown good correlation (r=0.89-0.96) with 24-hour liquid urine collections for sex steroid metabolites.
Can diet alone improve my 2-OHE1:16α-OHE1 ratio?
Yes. Three to five servings per week of cruciferous vegetables (broccoli, cauliflower, Brussels sprouts, kale) can increase 2-hydroxylation within 7 to 14 days. Combined with 25+ grams of daily fiber, 2 tablespoons of ground flaxseed, and reduced alcohol intake, dietary changes alone can improve the 2:16 ratio by 20 to 35% within 2 months.
Is DIM supplementation safe long-term?
DIM at 108 to 300 mg/day has been used in clinical trials lasting up to 12 months without serious adverse effects. Mild GI symptoms (nausea, changes in urine color) are the most common side effects. DIM should be avoided during pregnancy due to insufficient safety data. Patients on tamoxifen or aromatase inhibitors should consult their oncologist before starting DIM, as it may alter estrogen metabolism in ways that interact with these medications.
How does body weight affect urinary sex steroid metabolite results?
Excess adipose tissue increases aromatase activity, raising total estrogen production and preferentially shifting metabolism toward 16α-hydroxylation and 4-hydroxylation. Each 5-unit increase in BMI has been associated with a 15% decrease in the 2:16 ratio. Weight loss of 5-10% can measurably improve the metabolite pattern within 3 to 6 months.
Should men get urinary sex steroid metabolite testing?
Yes, particularly men on testosterone replacement therapy. The test reveals how exogenous testosterone is being metabolized (5α vs. 5β reduction), whether estrogen conversion is excessive, and whether protective methylation is adequate. Men with gynecomastia, prostate concerns, or unexplained mood changes on TRT benefit from this testing.
What is 2-methoxyestrone and why does it matter?
2-methoxyestrone (2-MeOE1) is produced when COMT methylates 2-OHE1. It is considered protective because methylation prevents the catechol estrogen from forming reactive quinone intermediates. Low 2-MeOE1 relative to 2-OHE1 suggests slow COMT activity, which can be supported with folate, B12, B6, magnesium, and by limiting high-dose COMT-inhibiting polyphenols like concentrated green tea extract.
Does green tea help or hurt estrogen metabolism?
This depends on context. Green tea polyphenols (especially EGCG) inhibit COMT, the enzyme that methylates catechol estrogens into protective methoxy forms. At normal dietary intake (1-3 cups/day), the effect is small. Concentrated EGCG supplements above 400 mg/day may meaningfully slow methylation, especially in individuals with the COMT Met/Met genotype. Patients with low 2-MeOE1 on testing should avoid high-dose green tea extracts.
How often should I retest urinary sex steroid metabolites?
Retest 60 to 90 days after implementing interventions. For premenopausal women, collect the sample on days 19-22 of the menstrual cycle (luteal phase) to match baseline conditions. Annual monitoring is reasonable for patients on HRT, TRT, or ongoing supplementation protocols. More frequent testing is rarely needed unless a major medication change occurs.
Can stress affect my results?
Chronic stress elevates cortisol, which shares precursor pathways with sex steroids (the pregnenolone steal concept). High cortisol output can reduce DHEA production and shift resources away from sex steroid synthesis. The DUTCH test captures both cortisol metabolites and sex steroid metabolites on the same panel, allowing clinicians to evaluate this relationship directly.

References

  1. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998;19(1):1-27. https://pubmed.ncbi.nlm.nih.gov/9472688/
  2. Fishman J, Martucci C. Biological properties of 16α-hydroxyestrone: implications in estrogen physiology and pathophysiology. J Clin Endocrinol Metab. 1980;51(3):611-615. https://pubmed.ncbi.nlm.nih.gov/7410532/
  3. Cavalieri EL, Rogan EG. Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention. Clin Transl Med. 2016;5(1):12. https://pubmed.ncbi.nlm.nih.gov/26979321/
  4. Rittmaster RS. 5α-Reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk. N Engl J Med. 2008;359(20):2091-2101. https://www.nejm.org/doi/full/10.1056/NEJMct0803089
  5. Arslan AA, Koenig KL, Lenner P, et al. Circulating estrogen metabolites and risk for breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1290-1297. https://pubmed.ncbi.nlm.nih.gov/24771666/
  6. Endocrine Society. Estrogen metabolism and risk assessment: scientific statement. J Clin Endocrinol Metab. 2006;91(10):3697-3710. https://academic.oup.com/jcem/article/91/10/3697/2656532
  7. Eliassen AH, Spiegelman D, Xu X, et al. Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res. 2012;72(3):696-706. https://pubmed.ncbi.nlm.nih.gov/22351927/
  8. Honour JW. Steroid profiling. Ann Clin Biochem. 1997;34(Pt 1):32-44. https://pubmed.ncbi.nlm.nih.gov/9022888/
  9. Fuhrman BJ, Schairer C, Gail MH, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2012;104(4):326-339. https://pubmed.ncbi.nlm.nih.gov/22232133/
  10. Falk RT, Brinton LA, Dorgan JF, et al. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk. J Clin Endocrinol Metab. 2013;98(11):E1775-E1780. https://academic.oup.com/jcem/article/98/11/E1775/2834810
  11. Michnovicz JJ, Adlercreutz H, Bradlow HL. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst. 1997;89(10):718-723. https://pubmed.ncbi.nlm.nih.gov/9168187/
  12. Dalessandri KM, Firestone GL, Fitch MD, et al. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004;50(2):161-167. https://pubmed.ncbi.nlm.nih.gov/15623462/
  13. Matthews CE, Fowke JH, Dai Q, et al. Physical activity, body size, and estrogen metabolism in women. Cancer Causes Control. 2004;15(5):473-481. https://pubmed.ncbi.nlm.nih.gov/15286466/
  14. Tworoger SS, Missmer SA, Eliassen AH, et al. Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations. Cancer Causes Control. 2007;18(7):743-752. https://pubmed.ncbi.nlm.nih.gov/17549594/
  15. Lachman HM, Papolos DF, Saito T, et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6(3):243-250. https://pubmed.ncbi.nlm.nih.gov/8807664/
  16. Fowke JH, Longcope C, Hebert JR. Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2000;9(8):773-779. https://pubmed.ncbi.nlm.nih.gov/10952093/
  17. Zhu BT, Liehr JG. Inhibition of catechol O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by quercetin. J Biol Chem. 1996;271(3):1357-1363. https://pubmed.ncbi.nlm.nih.gov/8576125/
  18. Gore AC, Chappell VA, Fenton SE, et al. EDC-2: The Endocrine Society's second scientific statement on endocrine-disrupting chemicals. Endocr Rev. 2015;36(6):E1-E150. https://academic.oup.com/edrv/article/36/6/E1/2354691
  19. Chang TKH, Chen J, Lee WBK. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol. J Pharmacol Exp Ther. 2001;298(2):537-544. https://pubmed.ncbi.nlm.nih.gov/11454913/
  20. Cavalieri EL, Rogan EG. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol. 2011;125(3-5):169-180. https://pubmed.ncbi.nlm.nih.gov/21397019/
  21. Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase. J Altern Complement Med. 2002;8(2):143-152. https://pubmed.ncbi.nlm.nih.gov/12006122/
  22. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341(14):1013-1020. https://www.nejm.org/doi/full/10.1056/NEJM199909303411401
  23. American Association of Clinical Endocrinologists. AACE guidelines for adrenal insufficiency management. Endocr Pract. 2020;26(Suppl 1):1-46. https://www.aace.com/disease-state-resources/adrenal
  24. Hartman TJ, Sisti JS, Hankinson SE, et al. Alcohol consumption and urinary estrogens and estrogen metabolites in premenopausal women. Horm Cancer. 2016;7(1):65-74. https://pubmed.ncbi.nlm.nih.gov/26728472/
  25. Goldin BR, Adlercreutz H, Gorbach SL, et al. Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. N Engl J Med. 1982;307(25):1542-1547. https://www.nejm.org/doi/full/10.1056/NEJM198212163072502
  26. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2009;18(1):74-79. https://pubmed.ncbi.nlm.nih.gov/19124483/